NASH |Abstract Library
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
Pharmacol Res. 2023 Mar;189:106679. doi: 10.1016/j.phrs.2023.106679.Epub 2023 Feb 8.
Manfredi Rizzo 1 , Alessandro Colletti 2 , Peter E Penson 3 , Niki Katsiki 4 , Dimitri P Mikhailidis 5 , Peter P Toth 6 , Ioanna Gouni-Berthold 7 , John Mancini 8 , David Marais 9 , Patrick Moriarty 10 , Massimiliano Ruscica 11 , Amirhossein Sahebkar 12 , Dragos Vinereanu 13 , Arrigo Francesco Giuseppe Cicero 14 , Maciej Banach 15 ; International Lipid Expert Panel (ILEP)
Author information
Collaborators
International Lipid Expert Panel (ILEP): Julio Acosta 16 , Mutaz Al-Khnifsawi 17 , Fahad Alnouri 18 , Fahma Amar 19 , Atanas G Atanasov 20 , Gani Bajraktari 21 , Maciej Banach 22 , Ioanna Gouni-Berthold 23 , Sonu Bhaskar 24 , Agata Bielecka-Dabrowa 25 , Bojko Bjelakovic 26 , Eric Bruckert 27 , Ibadete Bytyçi 28 , Alberto Cafferata 29 , Richard Ceska 30 , Arrigo F G Cicero 31 , Krzysztof Chlebus 32 , Xavier Collet 33 , Magdalena Daccord 34 , Olivier Descamps 35 , Dragan Djuric 36 , Ronen Durst 37 , Marat V Ezhov 38 , Zlatko Fras 39 , Dan Gaita 40 , Ioanna Gouni-Berthold 7 , Adrian V Hernandez 41 , Steven R Jones 42 , Jacek Jozwiak 43 , Nona Kakauridze 44 , Amani Kallel 45 , Niki Katsiki 46 , Amit Khera 47 , Karam Kostner 48 , Raimondas Kubilius 49 , Gustavs Latkovskis 50 , G B John Mancini 8 , A David Marais 9 , Seth S Martin 51 , Julio Acosta Martinez 52 , Mohsen Mazidi 53 , Dimitri P Mikhailidis 54 , Erkin Mirrakhimov 55 , Andre R Miserez 56 , Olena Mitchenko 57 , Natalya P Mitkovskaya 58 , Patrick M Moriarty 10 , Seyed Mohammad Nabavi 59 , Devaki Nair 60 , Demosthenes B Panagiotakos 61 , György Paragh 62 , Daniel Pella 63 , Peter E Penson 64 , Zaneta Petrulioniene 65 , Matteo Pirro 66 , Arman Postadzhiyan 67 , Raman Puri 68 , Ashraf Reda 69 , Željko Reiner 70 , Dina Radenkovic 71 , Michal Rakowski 72 , Jemaa Riadh 73 , Dimitri Richter 74 , Manfredi Rizzo 75 , Massimiliano Ruscica 11 , Amirhossein Sahebkar 12 , Maria-Corina Serban 76 , Abdullah M A Shehab 77 , Aleksandr B Shek 78 , Cesare R Sirtori 79 , Claudia Stefanutti 80 , Tomasz Tomasik 81 , Peter P Toth 42 , Margus Viigimaa 82 , Pedro Valdivielso 83 , Dragos Vinereanu 13 , Branislav Vohnout 84 , Stephan von Haehling 85 , Michal Vrablik 86 , Nathan D Wong 87 , Hung-I Yeh 88 , Jiang Zhisheng Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10-25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
Follow us